Zenith Epigenetics is a leading brand in the field of epigenetic research and therapy. With a team of experienced researchers and clinical collaborators, they have developed a cutting-edge epigenetic platform that produces differentiated, potent, and selective BET inhibitors. These inhibitors are used in the development of combination therapies for various oncology indications.

The brand places a strong emphasis on translational medicine, ensuring that patients who will benefit the most from their therapies are selected. Zenith's lead BET inhibitor, ZEN-3694, is currently in Phase 2 clinical development for the treatment of prostate cancer and breast cancer, in collaboration with Pfizer. With a focus on innovation and clinical development, Zenith Epigenetics is at the forefront of advancing the field of epigenetics in the fight against cancer